Imaging Study to Evaluate Heart Function and Treatment Outcomes After First-Time Acute Myocardial Infarction with Emergency PCI

What this Trial Is About

Researchers are evaluating the use of 18F-Pentixafor PETMR imaging in patients who have experienced their first acute myocardial infarction AMI and undergone interventional procedures such as percutaneous coronary intervention PCI or balloon angioplasty. The study aims to assess coronary microcirculatory function, cardiac function, myocardial viability, inflammatory response, and the effectiveness of these interventions. It also plans to perform risk stratification and prognostic analysis for these patients. The study will enroll 20 patients and involve several procedures including patient screening, informed consent, baseline assessments like medical history, laboratory tests, ECGs, and the specialized 18F-Pentixafor PETMR examination. Imaging results will be reviewed by expert physicians from Radiology and Nuclear Medicine. Baseline cardiac magnetic resonance CMR exams will be done within 7 days after PCI, with follow-up CMR at 6 months post-procedure to monitor changes over time. Participants will undergo various evaluations such as blood and urine tests, blood biochemistry, ECG, and imaging studies. The main outcomes measured include myocardial uptake of 18F-Pentixafor, left ventricular ejection fraction LVEF, and infarct characterization by PET and MRI imaging. Secondary outcomes include myocardial T1 and T2 values, extracellular volume, and strain analysis. The study will monitor patients from baseline through 6 months, aiming to provide detailed insights into heart function and recovery after AMI treatments.

Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction